A selective peroxisome proliferator-activated receptor-β/δ agonist attenuates neointimal hyperplasia after wire-mediated arterial injury

Author： Hamaya Rikuta  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.9, 2013-09, pp. : 1095-1106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases

By Bedu Elodie   Wahli Walter   Desvergne Béatrice  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 861-873

Informa Healthcare

Access to resources Recommend Favorite

High-Density Lipoprotein Cholesterol-Elevating Effect of a Novel Peroxisome Proliferator-Activated Receptor δ Agonist

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 6, 2011-07 ,pp. : 496-499

Bentham Science Publishers

Access to resources Recommend Favorite

Design, Synthesis, and Structure-Activity Relationship Study of Peroxisome Proliferator-Activated Receptor (PPAR) &dgr;-Selective Ligands

By  

Current Medicinal Chemistry, Vol. 14, Iss. 22, 2007-09 ,pp. : 2335-2343

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor-β as a target for wound healing drugs

By Tan Nguan Soon   Michalik Liliane   Desvergne Béatrice   Wahli Walter  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 1, 2004-02 ,pp. : 39-48

Informa Healthcare

Access to resources Recommend Favorite

Agonist of peroxisome proliferator-activated receptor gamma (PPAR-  ): a new compound with potent gastroprotective and ulcer healing properties

By Brzozowski Tomasz  

Inflammopharmacology, Vol. 13, Iss. 1-3, 2005-08 ,pp. : 317-330

VSP

Access to resources Recommend Favorite